Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA/Drug Safety Bill Moves Toward Senate Floor

This article was originally published in The Pink Sheet Daily

Executive Summary

Revisions to DTC and pediatric sections seem possible after ranking member Enzi supports two failed amendments.

You may also be interested in...



Follow-On Biologics, Drug Importation Get Split Decision From Bush Administration

Memo on potential amendments to FDA Revitalization Act threatens veto if importation provisions are attached and expresses concern about a generic biologic pathway but does not declare it unacceptable.

Follow-On Biologics, Drug Importation Get Split Decision From Bush Administration

Memo on potential amendments to FDA Revitalization Act threatens veto if importation provisions are attached and expresses concern about a generic biologic pathway but does not declare it unacceptable.

Pediatric Exclusivity Incentive Limited Under Draft PDUFA Bill

Products with more than $1 billion in sales would only get three months, and awards would only be given after labeling changes are made.

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel